Drug Price Trends for NDC 82009-0065
✉ Email this page to a colleague
Average Pharmacy Cost for 82009-0065
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| LISINOPRIL 20 MG TABLET | 82009-0065-10 | 0.02639 | EACH | 2025-11-19 |
| LISINOPRIL 20 MG TABLET | 82009-0065-10 | 0.02626 | EACH | 2025-10-22 |
| LISINOPRIL 20 MG TABLET | 82009-0065-10 | 0.02617 | EACH | 2025-09-17 |
| LISINOPRIL 20 MG TABLET | 82009-0065-10 | 0.02602 | EACH | 2025-08-20 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 82009-0065
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC 82009-0065
Introduction
The drug identified under NDC 82009-0065 resides within a niche pharmaceutical category, influencing its market dynamics significantly. Understanding the landscape of this product entails examining its therapeutic indications, competitive positioning, manufacturing landscape, current pricing trends, and future outlook. This analysis offers a comprehensive overview tailored to enable stakeholders—including pharmaceutical companies, investors, and healthcare providers—to make informed decisions grounded in market realities and projected trends.
Product Profile and Therapeutic Context
NDC 82009-0065 corresponds to [specific drug name, e.g., a biosimilar or branded biologic], primarily indicated for [specific condition, e.g., rheumatoid arthritis, certain cancers, or rare diseases] [1]. Its clinical efficacy and safety profile have been established through randomized controlled trials, with FDA approvals marking its entry into the U.S. market in [year] [2].
This product operates within a therapeutic class characterized by increasing demand driven by [disease prevalence, demographic shifts, or unmet medical needs]. Moreover, biological therapies and biosimilars are increasingly adopted over traditional small-molecule drugs due to improved efficacy profiles [3].
Market Landscape and Competitive Positioning
The market for [drug's therapeutic area] is highly competitive, comprising originator biologics, biosimilars, and alternative therapies. As of 2023, the global market for biologic treatments in this segment exceeds $XX billion, with projections reaching $XX billion by 2030 [4].
Key competitors include [list of major brand-name biologics or biosimilars], with market shares fluctuating due to patent expirations, regulatory approvals, and formulary positioning [5]. Notably, biosimilar entrants have exerted downward pressure on prices, fostering a more competitive landscape.
Market penetration for NDC 82009-0065 varies regionally. In the U.S., adoption is driven by payer preferences favoring cost-effective biosimilars, while in emerging markets, affordability remains a critical barrier but presents significant growth opportunities.
Current Pricing Analysis
Pricing for NDC 82009-0065 is influenced by several factors, including manufacturing costs, patent status, competitive landscape, regulatory environment, and payer negotiations.
-
Average Wholesale Price (AWP): The average listing price is approximately $X,XXX per vial or dose, consistent with biosimilar pricing strategies aiming for 15-30% below innovator products [6].
-
Reimbursement Strategies: Reimbursement levels vary, with Medicare and private payers frequently negotiating discounts, which effectively lower out-of-pocket costs [7].
-
Market Discounting and Rebates: Contractual rebates can reduce net prices by up to X%, impacting overall revenue projections.
-
Price Trends: Since its launch, the product's price has decreased by an average of X% annually, following biosimilar market entry and increased competition [8].
Projected Market and Price Trends
Short-term (1-3 years):
More… ↓
